MyShare
Key factors
| sym | ORMP |
| exch | US |
| MCap | 89.14M |
| Beta | 1.817 |
| PE Ratio | 15.71 |
| EPS | 0.14 |
| Div date | 0000-00-00 |
Yesterday
| sym | ORMP |
| exch | US |
| close | 2.27 |
| 50 Day MA | 2.921 |
| 200 Day MA | 2.687 |
| 52 Week High | 5.25 |
| 52 Week Low | 1.67 |
| Target Price | 4.25 |
| Market Cap Mln | 89.14 |
Share statistics
| Shares Outstanding | 40.51M |
| Shares Float | 36.69M |
| Percent Institutions | 13.87 |
| PercentInsiders | 11.23 |
| SharesShort | 583.94K |
| Short Ratio | 3.95 |
| Shares Short Prior Month | 484.01K |
| Short Percent | 1.590 |
Income
| Revenue TTM | 1340.0K |
| Revenue Per Share TTM | 0.033 |
| Quarterly Revenue Growth YOY | -100.0 |
| Gross Profit TTM | 2703.0K |
| EBITDA | -15.5M |
| Diluted Eps TTM | 0.14 |
earning
| Operating Margin TTM | -11.7 |
| Trailing PE | 15.71 |
| EPS Estimate Current Quarter | -0.08 |
| EPS Estimate Current Year | -0.31 |
| EPS Estimate Next Quarter | 0.02 |
| EPS Estimate Next Year | -0.26 |
| Earnings Share | 0.14 |
Dividend
| Dividend Date | 0000-00-00 |
| Last Split Date | 2013-01-23 |
| Last Split Factor | 1:12 |
business
| Enterprise Value Ebitda | -1.13 |
| Enterprise Value Revenue | 1.353 |
| Book Value /share | 4.061 |
| Price Book MRQ | 0.623 |
| Price Sales TTM | 76.20 |
| ProfitMargin | 4.123 |
| ReturnOnAssetsTTM | -0.05 |
| ReturnOnEquityTTM | 0.032 |
Sector
| Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry | Pharmaceuticals |
| Gic Sector | Health Care |
| Gic Sub Industry | Pharmaceuticals |
| Industry | Biotechnology |
| Sector | Healthcare |
Codes
| ISIN | US68403P2039 |
| CIK | 1176309 |
| Code | ORMP |
| CUSIP | 68403P104 |
| Employer Id Number | 98-0376008 |
| CountryISO | US |
| Currency Code | USD |
| Currency Name | US Dollar |
| Exchange | NASDAQ |
| Currency Symbol | $ |
fund
| Type | Common Stock |
| UpdatedAt | 2024-04-18 |
| Home Category | Domestic |
info
| Fiscal Year End | August |
| IPODate | 2006-04-21 |
| International Domestic | Domestic |
| MostRecent Quarter | 2023-11-30 |
Contact
| Name | Oramed Pharmaceuticals Inc |
| Address | 1185 Avenue of the Americas, New York, NY, United States, 10036 |
| Country Name | USA |
| Phone | 844 967 2633 |
| Web URL | https://www.oramed.com |
| Logo URL | /img/logos/US/ORMP.png |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.